Biogen is seeking approval of tofersen under the FDA’s accelerated approval pathway, based on the use of neurofilament as a surrogate biomarker. Decision expected 25 Jan 2023. Results from their phase 1 up to most recent phase 3 VALOR and OLE studies is included. Tofersen targets subtype of MND caused by SOD1 mutation. Click link to read news release.
